Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
- 1 June 1997
- Vol. 49 (6) , 913-920
- https://doi.org/10.1016/s0090-4295(97)00091-5
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancerUrology, 1995
- Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MAMolecular and Cellular Endocrinology, 1993
- IntracrinologyMolecular and Cellular Endocrinology, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Phase III studies to compare goserelin (zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinomaUrology, 1989
- Flutamide versus Stilboestrol in the Management of Advanced Prostatic Cancer: A Controlled Prospective StudyBritish Journal of Urology, 1988
- Flutamide as Primary Treatment for Metastatic Prostatic CancerBritish Journal of Urology, 1987
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancerUrology, 1976